Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as NN9925 (oral)
NN9925 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Trial part 1 | EXPERIMENTAL | - |
| Trial part 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| NN9925 (oral) | DRUG | Subjects will be randomised to receive a single dose of NN9925, at escalating dose levels. Progression to next dose will be based on safety evaluation |
| NN9925 (i.v.) | DRUG | As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit |
| placebo | DRUG | Subjects will receive a single dose of placebo as a comparator to NN9925, at all dose levels |
Inclusion Criteria: * Male subjects with good general health as judged by the physician * Body weight of 65-95 kg (both inclusive) * Body Mass Index (BMI) of 18.5-27.5 kg/m2 (both inclusive) Exclusion Criteria: * Known or suspected allergy to trial product or related products * Acute infection or...
NN9925 is an investigational oral small molecule developed by Novo Nordisk A/S for diabetes. It is an early stage clinical candidate that has been studied in a Phase 1 trial in healthy male subjects. NN9925 is also referred to as NN9925 (oral), reflecting its oral route of administration.
NN9925 is being developed for the treatment of diabetes, including type 2 diabetes mellitus. Its clinical testing to date has involved healthy male volunteers rather than patients with diabetes, so the program remains at an early investigational stage.
NN9925 is being developed by Novo Nordisk A/S, the Danish pharmaceutical company that trades under the ticker NVO. Novo Nordisk is the sponsor of the clinical program evaluating the compound.
NN9925 is in Phase 1 clinical development. It has not been approved by the FDA or any other regulatory authority and remains an investigational drug. One Phase 1 trial has been completed, and no active trials are currently listed for the compound.
NN9925 has been studied in a single Phase 1 trial, NCT01087645, titled "A Two Part Trial Investigating the Safety of NN9925 in Healthy Male Subjects." The trial enrolled 70 healthy male participants aged 18 years and older in the United Kingdom and has been completed.
The Phase 1 trial of NN9925, NCT01087645, was a randomized, double-blind, controlled study conducted in healthy male volunteers in the United Kingdom. It enrolled 70 participants and has been completed. The trial was designed to investigate the safety of NN9925.